What are the recommended dose, contraindications, monitoring requirements, and adverse effects of amiloride for treating hypertension and edema?

Amiloride for Hypertension and Edema

Amiloride is an effective potassium-sparing diuretic that should be considered as a fourth-line agent for resistant hypertension at doses of 10-20 mg daily, particularly when spironolactone is not tolerated, and it demonstrates comparable blood pressure reduction with fewer antiandrogenic side effects. 1

Recommended Dosing

For Hypertension (Resistant)

• Start with 5 mg daily when added to existing antihypertensive therapy 2
• Increase to 10 mg daily if blood pressure control is inadequate 2
• Maximum dose: 20 mg daily with careful electrolyte monitoring if persistent hypokalemia was previously documented 2
• The 2025 AHA/ACC guidelines specifically recommend 10-20 mg as the effective range for resistant hypertension 1

For Edema

• Initial: 5 mg daily with food 2
• Titration: Increase to 10 mg, then 15 mg, then 20 mg if needed, with careful electrolyte monitoring 2
• More than 10 mg daily has little controlled experience 2
• Maintenance therapy may be intermittent after initial diuresis is achieved 2

Administration

• Always administer with food to optimize absorption 2

Clinical Context and Evidence

The 2025 AHA/ACC guidelines position amiloride as an alternative when spironolactone (the preferred fourth-line agent) cannot be tolerated due to hyperkalemia or antiandrogenic effects (gynecomastia, menstrual irregularities), which affect 4-40% of patients 1. Recent evidence from the SPARE trial demonstrated non-inferiority to spironolactone, with home systolic blood pressure reductions of -13.6 mmHg versus -14.7 mmHg respectively 3.

Amiloride may be particularly effective in patients with higher body mass index and lower aldosterone-renin ratios, suggesting a distinct mechanism beyond aldosterone blockade 3. Unlike spironolactone, amiloride's efficacy remains consistent across varying renin and aldosterone levels 3.

Contraindications

Absolute Contraindications

• Hyperkalemia (serum potassium >5.5 mEq/L) 2
• Severe renal insufficiency - use cautiously if at all 4
• Concurrent use with other potassium-sparing diuretics or potassium supplements without close monitoring

Relative Contraindications

• Moderate renal impairment (eGFR <40 mL/min/1.73 m²) - requires dose adjustment and intensive monitoring 5
• Concurrent ACE inhibitor or ARB therapy - significantly increases hyperkalemia risk 5
• Hepatic dysfunction - can be used but requires caution 4

Monitoring Requirements

Essential Monitoring

• Serum potassium: Check at baseline, within 1-2 weeks of initiation, after each dose increase, and regularly thereafter

  • Critical threshold: Discontinue if potassium >5.5 mEq/L 2
  • In the SPARE trial, only 1 patient discontinued due to hyperkalemia 3
  • In resistant hypertension studies with diabetes, 9% developed hyperkalemia >5.5 mEq/L requiring discontinuation 6

• Renal function (eGFR/creatinine): Monitor closely as amiloride can cause acute kidney injury, particularly when combined with ACE inhibitors and spironolactone 5

  • One case report showed eGFR decrease from 41 to 29 mL/min with potassium rising to 7.8 mmol/L 5

• Blood pressure: Home and/or ambulatory monitoring preferred over office readings 1

  • Peak effect occurs at 3 hours with a 6-hour half-life 4

• Body weight and edema status: Particularly in nephrotic syndrome or heart failure 2

Monitoring Frequency

• Week 1-2: Potassium and creatinine
• After dose adjustments: Potassium and creatinine within 1 week
• Ongoing: Monthly for first 3 months, then every 3 months if stable

Adverse Effects

Most Common (>1%)

• Headache 2
• Nausea/anorexia (3-8% of patients) 2
• Diarrhea (3-8% of patients) 2
• Dizziness 2

Serious Adverse Effects

• Hyperkalemia (>5.5 mEq/L): Most significant concern, particularly when combined with ACE inhibitors, ARBs, or spironolactone 25

  • Can be life-threatening if potassium reaches >7.0 mEq/L 5

• Acute kidney injury: Especially in patients with baseline renal impairment or when combined with multiple RAAS inhibitors 5

Less Common (≤1%)

• Muscle cramps, weakness, fatigue 2
• Abdominal pain, flatulence 2
• Skin rash, pruritus 2
• Impotence, gynecomastia (significantly less than spironolactone) 23
• Encephalopathy (rare) 2

Rarely Reported

• Aplastic anemia, neutropenia 2
• Abnormal liver function 2
• GI bleeding 2

Critical Clinical Pitfalls

Hyperkalemia Risk Amplification

The most dangerous scenario occurs when amiloride is added to patients already on ACE inhibitors/ARBs AND spironolactone - this triple combination dramatically increases hyperkalemia risk 5. If using this combination, potassium monitoring must be weekly initially.

Nephrotic Syndrome Considerations

While amiloride can effectively resolve resistant edema in nephrotic syndrome by blocking aberrantly activated ENaC channels 56, the risk of dangerous hyperkalemia and acute kidney injury is substantially elevated in this population 5. The AMILOR trial showed similar efficacy to furosemide but requires further validation 7.

Dose-Response Uncertainty

Historical studies on amiloride in hypertension were poorly controlled with insufficient dose-response data 8. The effective range of 10-20 mg for resistant hypertension is based on recent guideline recommendations 1 rather than extensive dose-ranging trials.

Mechanism and Unique Properties

Amiloride blocks epithelial sodium channels (ENaC) in the late distal tubule and collecting duct, independent of aldosterone 84. Beyond renal effects, it may improve endothelial function by inhibiting vascular ENaC, reducing oxidative stress and vascular stiffness 3. This dual mechanism may explain its consistent efficacy across varying aldosterone levels.

In nephrotic syndrome, filtered plasminogen is activated to plasmin along the tubular system, which proteolytically activates ENaC, creating sodium retention 6. Amiloride both blocks ENaC and inhibits urokinase-type plasminogen activator, providing dual benefit 6.